Cargando…
High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
Mirabegron, which was the first β3-adrenoceptor agonist introduced for use in clinical practice, has been extensively evaluated in overactive bladder (OAB) patients in several phase II and III studies. However, most of the enrolled patients were treatment naive or had experienced a wash-out period b...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106046/ https://www.ncbi.nlm.nih.gov/pubmed/27828840 http://dx.doi.org/10.1097/MD.0000000000004962 |